| Literature DB >> 24815191 |
Jiegou Xu1, David B Alexander, Mitsuru Futakuchi, Takamasa Numano, Katsumi Fukamachi, Masumi Suzui, Toyonori Omori, Jun Kanno, Akihiko Hirose, Hiroyuki Tsuda.
Abstract
Multiwalled carbon nanotubes (MWCNT) have a fibrous structure similar to asbestos, raising concern that MWCNT exposure may lead to asbestos-like diseases. Previously we showed that MWCNT translocated from the lung alveoli into the pleural cavity and caused mesothelial proliferation and fibrosis in the visceral pleura. Multiwalled carbon nanotubes were not found in the parietal pleura, the initial site of development of asbestos-caused pleural diseases in humans, probably due to the short exposure period of the study. In the present study, we extended the exposure period to 24 weeks to determine whether the size and shape of MWCNT impact on deposition and lesion development in the pleura and lung. Two different MWCNTs were chosen for this study: a larger sized needle-like MWCNT (MWCNT-L; l = 8 μm, d = 150 nm), and a smaller sized MWCNT (MWCNT-S; l = 3 μm, d = 15 nm), which forms cotton candy-like aggregates. Both MWCNT-L and MWCNT-S suspensions were administered to the rat lung once every 2 weeks for 24 weeks by transtracheal intrapulmonary spraying. It was found that MWCNT-L, but not MWCNT-S, translocated into the pleural cavity, deposited in the parietal pleura, and induced fibrosis and patchy parietal mesothelial proliferation lesions. In addition, MWCNT-L induced stronger inflammatory reactions including increased inflammatory cell number and cytokine/chemokine levels in the pleural cavity lavage than MWCNT-S. In contrast, MWCNT-S induced stronger inflammation and higher 8-hydroxydeoxyguanosine level in the lung tissue than MWCNT-L. These results suggest that MWCNT-L has higher risk of causing asbestos-like pleural lesions relevant to mesothelioma development.Entities:
Keywords: Fibrosis; mesothelial proliferation; multiwalled carbon nanotubes; parietal pleura; pleural inflammation
Mesh:
Substances:
Year: 2014 PMID: 24815191 PMCID: PMC4317921 DOI: 10.1111/cas.12437
Source DB: PubMed Journal: Cancer Sci ISSN: 1347-9032 Impact factor: 6.716
Figure 1Evidence of multiwalled carbon nanotube (MWCNT) fibers in the pleura. Existence of MWCNT fibers in the parietal (a–c, g–i) and visceral (d–f, j–l) pleura of rats treated with larger sized MWCNT (MWCNT-L; l = 8 μm, d = 150 nm) (a–f) or smaller sized MWCNT (MWCNT-S; l = 3 μm, d = 15 nm) (g–l) was examined by polarized light microscopy (PLM) (d, e, h, k) and SEM (c, f, i, l). The area in (a) denoted by the square was subjected to SEM observation, shown in (c). Arrows indicate MWCNT fibers. PC, pleural cavity.
Figure 2Azan–Mallory (Azan) staining and thickness of the parietal and visceral pleura. (a) Azan–Mallory staining images and polarized light microscopy (PLM) images of the parietal and visceral pleura in rats sprayed with larger sized multiwalled carbon nanotubes (MWCNT-L; l = 8 μm, d = 150 nm) or smaller sized MWCNT (MWCNT-S; l = 3 μm, d = 15 nm). (b) Quantification of the thickness of the parietal and visceral pleura of rats treated with Pluronic F68 (PF68), MWCNT-L, or MWCNT-S on the basis of Azan–Mallory stained images. *P < 0.05 versus PF68; ***P < 0.001 versus PF68; †††P < 0.001 MWCNT-L versus MWCNT-S by two-tailed Student's t-test. Arrows indicate MWCNT fibers.
Figure 3Cell proliferation of the parietal and visceral mesothelium. (a) Representative proliferating cell nuclear antigen (PCNA) immunostained images of the parietal and visceral pleural regions of rats treated with larger sized multiwalled carbon nanotubes (MWCNT-L; l = 8 μm, d = 150 nm) or smaller sized MWCNT (MWCNT-S; l = 3 μm, d = 15 nm). (b) PCNA indices (percentages of PCNA positive mesothelial cells in total mesothelial cells). Scale bar = 20 μm. **P < 0.01 versus Pluronic F68 (PF68); ††P < 0.01 MWCNT-L versus MWCNT-S.
Figure 4Demonstration of multiwalled carbon nanotube (MWCNT) fibers and analysis of inflammatory reactions in the pleural cavity. (a) H&E staining, polarized light microscopy (PLM), and SEM images of pleural cell pellets taken from rats treated with larger sized MWCNT (MWCNT-L; l = 8 μm, d = 150 nm) or smaller sized MWCNT (MWCNT-S; l = 3 μm, d = 15 nm). Arrows indicate MWCNT fibers. (b–d) Analysis of leukocyte number (b), proportion of CD 68-positive cells (c), and protein concentration (d) in the supernatants of pleural cavity lavages. ***P < 0.001 versus Pluronic F68 (PF68); #P < 0.05, ##P < 0.01, and ###P < 0.001 MWCNT-L versus MWCNT-S by two-tailed Student's t-test. NT, no treatment.
Cytokines/chemokines in the pleural cavity lavage and lung tissue of rats treated with multiwalled carbon nanotubes (MWCNT)
| Cytokines/chemokines | Pleural cavity lavage (pg/mL) | Lung tissue (pg/mg protein) | ||||
|---|---|---|---|---|---|---|
| PF68 | MWCNT-L | MWCNT-S | PF68 | MWCNT-L | MWCNT-S | |
| G-CSF | n.d. | n.d. | n.d. | n.d. | n.d. | n.d. |
| GM-CSF | n.d. | n.d. | n.d. | n.d. | n.d. | n.d. |
| MIP1α | n.d. | n.d. | n.d. | 63.8 ± 16.2 | 120.7 ± 21.0*** | 331.5 ± 90.4***,††† |
| MIP2 | n.d. | n.d. | n.d. | 12.4 ± 6.1 | 27.2 ± 4.9*** | 59.7 ± 16.7***,†† |
| MCP1 | n.d. | n.d. | n.d. | 18.0 ± 13.9 | 39.1 ± 16.3* | 213.1 ± 45.8***,††† |
| TNF-α | n.d. | n.d. | n.d. | n.d. | n.d. | n.d. |
| IFN-γ | n.d. | n.d. | n.d. | n.d. | n.d. | n.d. |
| GRO/KC | n.d. | n.d. | n.d. | 425.2 ± 194.3 | 1105.4 ± 395.7** | 1353.1 ± 362.6*** |
| IP10 | 1.5 ± 1.5 | 8.9 ± 2.3***,††† | 2.3 ± 2.3 | 35.6 ± 5.8 | 49.9 ± 4.4*** | 64.0 ± 11.0***,† |
| RANTES | 3.8 ± 0.9 | 6.9 ± 1.9***,††† | 4.1 ± 0.7 | 556.0 ± 128.6 | 531.7 ± 127.9†† | 335.4 ± 61.3** |
| IL-1α | n.d. | n.d. | n.d. | 56.9 ± 14.4 | 85.3 ± 7.3** | 84.5 ± 14.0** |
| IL-1β | n.d. | n.d. | n.d. | 73.0 ± 19.3 | 103.7 ± 18.6* | 154.5 ± 17.6***,††† |
| IL-4 | n.d. | n.d. | n.d. | 3.7 ± 3.0 | 4.2 ± 3.4 | 3.8 ± 1.9 |
| IL-2 | 1.2 ± 1.9 | 14.1 ± 5.5***,†† | 5.2 ± 5.9 | 18.3 ± 4.1 | 18.9 ± 3.0 | 20.3 ± 7.7 |
| IL-6 | n.d. | n.d. | n.d. | 29.1 ± 14.1 | 27.0 ± 13.5 | 32.6 ± 13.4 |
| IL-12p70 | n.d. | n.d. | n.d. | n.d. | n.d. | n.d. |
| IL-17α | n.d. | n.d. | n.d. | n.d. | n.d. | n.d. |
| IL-18 | 66.3 ± 17.0 | 108.4 ± 25.1**,† | 70.4 ± 21.5 | 2294.8 ± 495.2 | 2471.8 ± 391.7 | 3085.6 ± 418.4*,† |
| VEGF | n.d. | n.d. | n.d. | 111.0 ± 24.0 | 99.1 ± 14.4 | 201.4 ± 13.8***,††† |
| EGF | n.d. | n.d. | n.d. | n.d. | n.d. | n.d. |
Data are expressed as mean ± standard deviation, n = 6 in each treatment group. *P < 0.05, **P < 0.01, ***P < 0.001, larger sized MWCNT (MWCNT-L; l = 8 μm, d = 150 nm) or smaller sized MWCNT (MWCNT-S; l = 3 μm, d = 15 nm) versus Pluronic F68 (PF68). †P < 0.05, ††P < 0.01, †††P < 0.001, MWCNT-L versus MWCNT-S. EGF, epidermal growth factor; G-CSF, granulocyte colony-stimulating factor; GM-CSF, granulocyte/macrophage colony-stimulating factor; GRO/KC, growth related oncogene/ keratinocyte-derived cytokine; IFNγ, γ-interferon; IL, interleukin; IP-10, interferon gamma-induced protein 10; n.d., not detectable; TNF-α, tumor necrosis factor-α; MCP1, monocyte chemotactic protein 1; MIP, macrophage inflammatory protein; RANTES, regulated on activation, normal T cell expressed and secreted; VEGF, vascular endothelial growth factor.